NCT01464242View on ClinicalTrials.gov

Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2015

Study Completion Date

December 31, 2015

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

Meglumine antimonate

Glucantime® 20mg/kg/day IM daily for 20 days

DRUG

Placebo

Placebo 400mg orally 3 times a day for 20 days

DRUG

Pentoxifylline

Pentoxifylline 400mg orally 3 times a day for 20 days

Trial Locations (1)

5930

Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas, Santiago de Cali

All Listed Sponsors
lead

Centro Internacional de Entrenamiento e Investigaciones Médicas

OTHER

NCT01464242 - Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis | Biotech Hunter | Biotech Hunter